Compound E, chemically designated as 209986-17-4 (CAS), represents a significant exploration within the field of Alzheimer's condition research. This γ-secretase blocking agent was initially developed as a possible therapeutic intervention aimed at reducing the production of amyloid-beta peptides, which are believed to be key contributors to the f